©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 110-114, 2026 ISSN: 2579-0781

https://doi.org/10.59298/IDOSR/JES/06/122110114 IDOSRJES12206

Reprogramming Metabolic Dysfunction using Nanotechnology: Implications for Obesity and Type 2 Diabetes

Nakawungu Catherine

Department of Pharmaceutical Microbiology and Biotechnology Kampala International University Uganda

Email: catherine.nakawungu@studwc.kiu.ac.ug

ABSTRACT

Obesity and type 2 diabetes (T2D) represent a major global health burden, with increasing prevalence linked to sedentary lifestyles, poor dietary habits, and genetic predisposition. These conditions are strongly interconnected through a range of metabolic dysfunctions, including insulin resistance, chronic inflammation, and dysregulated lipid metabolism. Traditional treatment approaches for obesity and T2D have been limited in their ability to address the underlying causes of metabolic dysfunction. Nanotechnology, however, presents a promising avenue for reprogramming these metabolic disturbances by enabling precise modulation of molecular pathways involved in insulin resistance, adiposity, and glucose homeostasis. Through the development of targeted drug delivery systems, biomolecular modulation, and tissue-specific therapies, nanomedicine offers the potential to reprogram metabolic dysfunction at the molecular level. This review explores the role of nanotechnology in targeting key metabolic processes involved in obesity and T2D, including inflammation, lipid metabolism, and insulin signaling. We also discuss the clinical prospects, challenges, and future directions of nanotechnology-based approaches in reprogramming metabolic dysfunction and improving therapeutic outcomes for patients with obesity-related diabetes.

Keywords: Nanotechnology, Metabolic Dysfunction, Obesity, Type 2 Diabetes, Targeted Therapy.

INTRODUCTION

Obesity and type 2 diabetes (T2D) are two of the most prevalent chronic diseases worldwide, and they are often closely associated due to the shared metabolic dysfunctions that underpin both conditions. Obesity, characterized by excessive accumulation of adipose tissue, particularly visceral fat, is a major contributor to the development of insulin resistance, a hallmark of T2D[1–3]. This metabolic dysfunction not only impairs glucose metabolism but also leads to chronic inflammation, altered lipid metabolism, and changes in adipokine secretion, all of which exacerbate insulin resistance and promote the progression of diabetes[4–6].

The pathophysiology of obesity-driven T2D is complex, involving a cascade of biochemical and molecular changes that disrupt normal metabolic function[7, 8]. These include the accumulation of free fatty acids (FFAs), altered gene expression in adipose tissue, the release of pro-inflammatory cytokines, and impaired insulin signaling pathways in tissues such as the liver, muscle, and adipose tissue[9–11]. Although traditional therapies, such as pharmacological agents and lifestyle interventions, have shown some success in managing these conditions, they often fail to address the underlying mechanisms driving metabolic dysfunction[12].

Nanotechnology offers a potential solution by enabling the precise reprogramming of these metabolic pathways[13–16]. Through the use of nanoparticles, nanocarriers, and biomolecular modulators, nanomedicine can target the root causes of insulin resistance, inflammation, and dysregulated lipid metabolism, providing a more efficient and tailored approach to managing obesity and T2D[17, 18]. This review examines how nanotechnology can be used to reprogram metabolic dysfunction in these diseases, with a focus on targeted therapy, drug delivery, and molecular modulation. We also explore the clinical potential and challenges associated with implementing these novel strategies in clinical settings.

Pathophysiology of Obesity-Driven Metabolic Dysfunction

The metabolic dysfunction observed in obesity and T2D is driven by a combination of genetic and environmental factors that lead to the disruption of normal metabolic processes. One of the central features of obesity is the accumulation of excess visceral fat, which is metabolically active and secretes various pro-inflammatory cytokines known as adipokines[19, 20]. These include TNF-α, IL-6, resistin, and leptin, which contribute to chronic low-grade inflammation in adipose tissue. This inflammation impairs insulin signaling by interfering with key proteins involved in glucose uptake, such as the insulin receptor substrate (IRS) and phosphatidylinositol 3-kinase (PI3K), leading to insulin resistance[21].

In addition to inflammation, obesity results in dysregulated lipid metabolism, particularly the accumulation of free fatty acids (FFAs) in the bloodstream. Excess FFAs are stored in non-adipose tissues, such as the liver and skeletal muscle, where they interfere with insulin sensitivity and promote the development of insulin resistance[21–24]. In the liver, the accumulation of lipids contributes to the development of non-alcoholic fatty liver disease (NAFLD), which is commonly seen in individuals with obesity and T2D. This further exacerbates the insulin resistance seen in obesity-driven T2D[25].

The pancreas plays a crucial role in maintaining glucose homeostasis through the secretion of insulin. However, in the context of insulin resistance, there is an increased demand for insulin production[26]. This puts a strain on pancreatic β-cells, leading to their dysfunction and eventual failure. This progression contributes to the development of hyperglycemia and the onset of T2D. Additionally, obesity-related changes in gut microbiota composition have been implicated in metabolic dysfunction, further complicating the pathophysiology of these diseases[26].

Nanotechnology offers the potential to target the key molecular pathways involved in obesity and T2D, including inflammation, lipid metabolism, and insulin signaling. By reprogramming these pathways at the molecular level, nanomedicine can help to restore normal metabolic function and improve insulin sensitivity.

Targeted Drug Delivery and Nanotechnology in Obesity and Diabetes Therapy

One of the most promising applications of nanotechnology in the treatment of obesity and T2D is the development of targeted drug delivery systems. Traditional drug delivery methods often suffer from poor bioavailability, off-target effects, and non-specific distribution[27]. Nanoparticles, due to their small size and large surface area, can be engineered to enhance drug delivery to specific tissues and organs, ensuring that therapeutic agents are released directly at the site of action[27].

Lipid-based nanoparticles, such as liposomes and solid lipid nanoparticles (SLNs), are commonly used to encapsulate hydrophobic drugs that are poorly soluble in water. These nanoparticles can be functionalized with targeting ligands, such as peptides, antibodies, or small molecules, to increase their specificity for particular cells involved in the obesity–diabetes crosstalk[28, 29]. For example, nanoparticles can be designed to target insulin-resistant adipocytes, pancreatic β-cells, or hepatocytes, delivering therapeutic agents precisely where they are needed most.

Polymeric nanoparticles offer another approach to targeted drug delivery. These nanoparticles can be engineered to release their cargo in response to specific environmental stimuli, such as changes in pH, temperature, or enzymatic activity, ensuring that drugs are released in a controlled manner[30–32]. This controlled release helps to maintain therapeutic drug levels over time, reducing the need for frequent administration and improving treatment efficacy.

Furthermore, multifunctional nanoparticles can be designed to carry a combination of therapeutic agents[30, 31]. For instance, a single nanoparticle could carry anti-inflammatory agents, insulin-sensitizing compounds, and agents that regulate lipid metabolism, providing a holistic approach to treating obesity and T2D.

Reprogramming Inflammation and Insulin Sensitivity via Nanotechnology

Chronic inflammation is a key driver of insulin resistance and metabolic dysfunction in both obesity and T2D. Nanotechnology offers a powerful tool for modulating inflammatory pathways and improving insulin sensitivity[33]. By using nanoparticles to deliver anti-inflammatory agents directly to the site of inflammation, nanomedicine can reduce the systemic inflammatory response that contributes to insulin resistance[33].

Nanoparticles can be engineered to deliver small molecules, such as cytokine inhibitors or NF-κB inhibitors, that target key inflammatory cytokines involved in the development of insulin resistance. For example, nanoparticles can be designed to deliver agents that block the activity of TNF-α, IL-6, or resistin, thereby reducing the inflammatory response in adipose tissue and improving insulin sensitivity[30, 34–36]. This localized delivery of anti-inflammatory agents not only reduces systemic inflammation but also enhances the bioavailability and effectiveness of the drug.

Nanotechnology can also be used to modulate insulin sensitivity by delivering insulin-sensitizing agents, such as metformin, thiazolidinediones (TZDs), or glucagon-like peptide-1 (GLP-1) agonists[37]. These agents can be delivered directly to tissues such as the liver, skeletal muscle, and adipose tissue, where they can enhance insulin signaling and improve glucose uptake. The controlled release of insulin-sensitizing agents using nanocarriers can help maintain therapeutic levels of the drug over an extended period, improving treatment efficacy and patient compliance.

Modulating Lipid Metabolism and Adipogenesis with Nanotechnology

Dysregulated lipid metabolism and adipogenesis (the formation of new fat cells) are hallmark features of obesity and T2D[38]. Nanotechnology offers a promising strategy for regulating these processes at the molecular level. By targeting key enzymes and transcription factors involved in lipid accumulation and adipocyte differentiation, nanomedicine can help reprogram lipid metabolism and reduce excess fat accumulation[38]. For example, nanoparticles can be used to deliver small molecules that inhibit the differentiation of pre-adipocytes into mature adipocytes. This can help reduce adiposity and prevent the development of obesity-related insulin resistance[39]. Nanoparticles can also be designed to deliver agents that regulate lipogenesis (fat synthesis) and promote lipolysis (fat breakdown), thus reprogramming lipid metabolism to improve insulin sensitivity.

Furthermore, nanotechnology can be used to regulate key metabolic enzymes, such as AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC), which play critical roles in lipid metabolism. By modulating these enzymes, nanomedicine can enhance fatty acid oxidation, reduce fat accumulation, and improve overall metabolic function.

Clinical Prospects and Challenges in Reprogramming Metabolic Dysfunction with Nanotechnology

While the potential of nanotechnology in treating obesity and T2D is substantial, several challenges remain in translating these therapies from the laboratory to clinical practice. One of the major obstacles is the safety and biocompatibility of nanoparticles[40]. Although nanomaterials offer several advantages, their small size and large surface area can lead to accumulation in vital organs, such as the liver, kidneys, and spleen. Thorough toxicological assessments and long-term safety studies are necessary to ensure that nanomedicines are safe for human use[40].

Another challenge is the complexity of metabolic dysfunction, which involves multiple interconnected pathways. Nanomedicine offers the potential to target these pathways simultaneously, but the development of multifunctional nanoparticles that can effectively modulate multiple targets is a significant challenge[41]. Additionally, the variability in patient responses to nanomedicine, particularly in diverse populations, may complicate the clinical implementation of these therapies.

Regulatory approval is also a major challenge for the widespread use of nanomedicine. Regulatory agencies, such as the FDA, are still in the process of developing guidelines for the approval of nanomedicines[42]. Ensuring that nanomedicines meet safety, efficacy, and quality standards is crucial for their successful integration into clinical practice.

CONCLUSION

Reprogramming metabolic dysfunction using nanotechnology offers a promising strategy for treating obesity and type 2 diabetes. By targeting key molecular pathways involved in inflammation, lipid metabolism, and insulin resistance, nanomedicine provides a more precise and efficient approach to managing these complex diseases. However, challenges related to safety, patient variability, and regulatory approval must be addressed before nanotechnology-based therapies can be widely adopted in clinical settings. With continued research and development, nanomedicine holds the potential to revolutionize the treatment of obesity and diabetes, offering personalized and highly effective therapies that can improve patient outcomes and reduce the global burden of metabolic diseases.

REFERENCES

1. Baliou, S., Apetroaei, M.-M., Hatzidaki, E., Kuzmin, S.V., Tzatzarakis, M.N., Arsene, A.L., Tsatsakis, A., Ioannou, P.: The Interplay Between Obesity and Type 2 Diabetes: Common Pathophysiological Mechanisms Contributing to Telomere Shortening. Life. 15, (2025). https://doi.org/10.3390/life15060873
2. Anguita-Ruiz, A., Bustos-Aibar, M., Plaza-Díaz, J., Mendez-Gutierrez, A., Alcalá-Fdez, J., Aguilera, C.M., Ruiz-Ojeda, F.J.: Omics Approaches in Adipose Tissue and Skeletal Muscle Addressing the Role of Extracellular Matrix in Obesity and Metabolic Dysfunction. Int. J. Mol. Sci. 22, 2756 (2021). https://doi.org/10.3390/ijms22052756
3. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
4. Ormazabal, P., Bastías-Pérez, M., Inestrosa, N.C., Cisternas, P.: Adipokines at the Metabolic–Brain Interface: Therapeutic Modulation by Antidiabetic Agents and Natural Compounds in Alzheimer's Disease. Pharmaceuticals. 18, (2025). https://doi.org/10.3390/ph18101527
5. Roy, P.K., Islam, J., Lalhlenmawia, H.: Prospects of potential adipokines as therapeutic agents in obesity-linked atherogenic dyslipidemia and insulin resistance. Egypt. Heart J. 75, 24 (2023). https://doi.org/10.1186/s43044-023-00352-7
6. Ejemot-Nwadiaro, R.I., Betiang, P.A., Basajja, M.: Obesity and Climate Change: A Two-way Street with Global Health Implications. Obes. Med. 100623 (2025). https://doi.org/10.1016/j.obmed.2025.100623
7. Omang, W.A., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Targeting CD44-Hyaluronic Acid Signalling in Obesity Treatment: Insights from Small Molecules and Nanobioconjugates. Nutr. Metab. Insights. 19, 11786388251408961 (2026). https://doi.org/10.1177/11786388251408961

8. Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
9. Martínez Báez, A., Ayala, G., Pedroza-Saavedra, A., González-Sánchez, H.M., Chihu Amparan, L.: Phosphorylation Codes in IRS-1 and IRS-2 Are Associated with the Activation/Inhibition of Insulin Canonical Signaling Pathways. Curr. Issues Mol. Biol. 46, 634–649 (2024). https://doi.org/10.3390/cimb46010041
10. Sayem, A.S.M., Arya, A., Karimian, H., Krishnasamy, N., Ashok Hasamnis, A., Hossain, C.F.: Action of Phytochemicals on Insulin Signaling Pathways Accelerating Glucose Transporter (GLUT4) Protein Translocation. Molecules. 23, 258 (2018). https://doi.org/10.3390/molecules23020258
11. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
12. Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
13. Ahmad, U., Islam, A., Khan, M.M., Akhtar, J.: Nanotechnology-driven Epigenetic Cancer Therapy: Precision Delivery and Sustained Release of DNA Methylation Modulators. Yale J. Biol. Med. 98, 227–235 (2025). https://doi.org/10.59249/GVNM8843
14. Alghamdi, M.A., Fallica, A.N., Virzì, N., Kesharwani, P., Pittalà, V., Greish, K.: The Promise of Nanotechnology in Personalized Medicine. J. Pers. Med. 12, 673 (2022). https://doi.org/10.3390/jpm12050673
15. Azmi, N.A.N., Elgharbawy, A.A.M.: Advances in Medical Applications: The Quest of Green Nanomaterials. In: Shanker, U., Hussain, C.M., and Rani, M. (eds.) Handbook of Green and Sustainable Nanotechnology: Fundamentals, Developments and Applications. pp. 1889–1909. Springer International Publishing, Cham (2023)
16. Dacoba, T.G., Olivera, A., Torres, D., Crecente-Campo, J., Alonso, M.J.: Modulating the immune system through nanotechnology. Semin. Immunol. 34, 78–102 (2017). https://doi.org/10.1016/j.smim.2017.09.007
17. Priya, Chaudhary, A., Rejeeth, C., Kumar, S., Ding, X., Sharma, A.: Exploring plant-based metallic nanoparticles for advanced medicinal application in diabetes. Nanotechnol. 8, 100243 (2025). https://doi.org/10.1016/j.nxnano.2025.100243
18. Zhang, M., Liu, E., Cui, Y., Huang, Y.: Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer. Cancer Biol. Med. 14, 212–227 (2017). https://doi.org/10.20892/j.issn.2095-3941.2017.0054
19. Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., Xu, Q.: Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front. Endocrinol. 14, 1161521 (2023). https://doi.org/10.3389/fendo.2023.1161521
20. Heindel, J.J., Blumberg, B., Cave, M., Machtinger, R., Mantovani, A., Mendez, M.A., Nadal, A., Palanza, P., Panzica, G., Sargis, R., Vandenberg, L.N., vom Saal, F.: Metabolism disrupting chemicals and metabolic disorders. Reprod. Toxicol. 68, 3–33 (2017). https://doi.org/10.1016/j.reprotox.2016.10.001
21. Choi, W., Woo, G.H., Kwon, T.-H., Jeon, J.-H.: Obesity-Driven Metabolic Disorders: The Interplay of Inflammation and Mitochondrial Dysfunction. Int. J. Mol. Sci. 26, (2025). https://doi.org/10.3390/ijms26199715
22. Suren Garg, S., Kushwaha, K., Dubey, R., Gupta, J.: Association between obesity, inflammation and insulin resistance: Insights into signaling pathways and therapeutic interventions. Diabetes Res. Clin. Pract. 200, 110691 (2023). https://doi.org/10.1016/j.diabres.2023.110691
23. Alexaki, V.I.: Adipose tissue-derived mediators of systemic inflammation and metabolic control. Curr. Opin. Endocr. Metab. Res. 37, 100560 (2024). https://doi.org/10.1016/j.coemr.2024.100560
24. Bera, R., Pathak, S., Srivastava, P., Ghosh, M., Sharma, A., Ahmed, N.Z., Karwasra, R., Akram, U., Kumar, P., Sharma, B., Sharma, N.: Biomimetic nanocarriers for the therapy and management of intestinal inflammations. Int. J. Pharm. X. 10, 100377 (2025). https://doi.org/10.1016/j.ijpx.2025.100377
25. Khin, P.P., Lee, J.H., Jun, H.-S.: Pancreatic Beta-cell Dysfunction in Type 2 Diabetes. Eur. J. Inflamm. 21, 1721727X231154152 (2023). https://doi.org/10.1177/1721727X231154152
26. De la Cruz-Concepción, B., Flores-Cortez, Y.A., Barragán-Bonilla, M.I., Mendoza-Bello, J.M., Espinoza-Rojo, M.: Insulin: A connection between pancreatic β cells and the hypothalamus. World J. Diabetes. 14, 76–91 (2023). https://doi.org/10.4239/wjd.v14.i2.76
27. Simos, Y.V., Spyrou, K., Patila, M., Karouta, N., Stamatis, H., Gournis, D., Dounousi, E., Peschos, D.: Trends of nanotechnology in type 2 diabetes mellitus treatment. Asian J. Pharm. Sci. 16, 62–76 (2021). https://doi.org/10.1016/j.ajps.2020.05.001

28. Waheed, I., Ali, A., Tabassum, H., Khatoon, N., Lai, W.-F., Zhou, X.: Lipid-based nanoparticles as drug delivery carriers for cancer therapy. Front. Oncol. 14, (2024). https://doi.org/10.3389/fonc.2024.1296091
29. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
30. Eltaib, L.: Polymeric Nanoparticles in Targeted Drug Delivery: Unveiling the Impact of Polymer Characterization and Fabrication. Polymers. 17, (2025). https://doi.org/10.3390/polym17070833
31. Herdiana, Y., Wathoni, N., Shamsuddin, S., Muchtaridi, M.: Scale-up polymeric-based nanoparticles drug delivery systems: Development and challenges. OpenNano. 7, 100048 (2022). https://doi.org/10.1016/j.onano.2022.100048
32. Nwuruku, O.A., Edwin, N.: Harnessing nature: plant-derived nanocarriers for targeted drug delivery in cancer therapy. Phytomedicine Plus. 5, 100828 (2025). https://doi.org/10.1016/j.phyplu.2025.100828
33. Rohm, T.V., Meier, D.T., Olefsky, J.M., Donath, M.Y.: Inflammation in obesity, diabetes, and related disorders. Immunity. 55, 31–55 (2022). https://doi.org/10.1016/j.immuni.2021.12.013
34. Ghadami, A., Fathi-karkan, S., Siddiqui, B., Gondal, S.A., Rahdar, A., Garousi, N.A., Kharaba, Z., Ghotekar, S.: Nanotechnology in Imatinib delivery: advancing cancer treatment through innovative nanoparticles. Med. Oncol. 42, 116 (2025). https://doi.org/10.1007/s12032-025-02660-1
35. Omang, W.A., Bawa, I., Idowu, A.O., Atangwho, I.J., Egbung, G.E.: Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia-Induced Glycolysis by Targeting Hypoxia-Inducible Factor-1 Alpha and Downstream Metabolites. Cancer Med. 15, e71519 (2026). https://doi.org/10.1002/cam4.71519
36. Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
37. Conroy, L.J., McCann, A., Zhang, N., de Gaetano, M.: The role of nanosystems in the delivery of glucose-lowering drugs for the preemption and treatment of diabetes-associated atherosclerosis. Am. J. Physiol.-Cell Physiol. 326, C1398–C1409 (2024). https://doi.org/10.1152/ajpcell.00695.2023
38. Kumar, S., Gupta, A.: From Molecules to Medicine: Deciphering Obesity and Lipid Metabolism for Translational Insights. Biomedicines. 14, 68 (2025). https://doi.org/10.3390/biomedicines14010068
39. Lorenzo-Anota, H.Y., Gómez-Cantú, J.M., Vázquez-Garza, E., Bernal-Ramirez, J., Chapoy-Villanueva, H., Mayolo-Deloisa, K., Benavides, J., Rito-Palomares, M., Lozano, O.: Disulfiram-Loaded Nanoparticles Inhibit Long-Term Proliferation on Preadipocytes. Int. J. Nanomedicine. 19, 13301–13318 (2024). https://doi.org/10.2147/IJN.S467909
40. Kaushal, A., Musafir, A., Sharma, G., Rani, S., Singh, R.K., Kumar, A., Bhadada, S.K., Barnwal, R.P., Singh, G.: Revolutionizing Diabetes Management Through Nanotechnology-Driven Smart Systems. Pharmaceutics. 17, (2025). https://doi.org/10.3390/pharmaceutics17060777
41. Nanotechnology to target autophagy-mediated metabolic disorders. In: Nanobiomaterials and Nanomedicines for Metabolic Disorders. pp. 421–474. Elsevier (2026)
42. Mühlebach, S.: Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach? Adv. Drug Deliv. Rev. 131, 122–131 (2018). https://doi.org/10.1016/j.addr.2018.06.024

CITE AS: Nakawungu Catherine (2026). Reprogramming Metabolic Dysfunction using Nanotechnology: Implications for Obesity and Type 2 Diabetes. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 110-114.
https://doi.org/10.59298/IDOSR/JES/06/122110114